Company RenovoRx, Inc.

Equities

RNXT

US75989R1077

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.243 ^USD	+2.73%		+6.24%	-45.72%

Apr. 16	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	CI
Apr. 15	RenovoRx, Inc. announced that it has received $11.136652 million in funding	CI

RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapyâs toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.

Number of employees: 8

Managers	Title	Age	Since
Shaun Bagai CEO	Chief Executive Officer	47	14-05-31
Ramtin Agah FOU	Founder	58	09-11-30
Ronald Kocak DFI	Director of Finance/CFO	67	21-09-30
Leesa Gentry PRN	Corporate Officer/Principal	54	23-04-24

Members of the board	Title	Age	Since
Una Ryan BRD	Director/Board Member	82	11-12-31
Laurence Marton BRD	Director/Board Member	80	12-11-30
Kristen MacFarlane BRD	Director/Board Member	60	18-08-31
Robert Spiegel BRD	Director/Board Member	73	23-04-24
Ramtin Agah FOU	Founder	58	09-11-30
Shaun Bagai CEO	Chief Executive Officer	47	14-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	16,865,975	15,215,717 ( 90.22 %)	0	90.22 %

Name	Equities	%	Valuation
Najmabadi Kamran /Estate Of/ 9.211 %	985,000	9.211 %	1 M $
Bank of the West (San Francisco, CA Investment Management) 9.118 %	975,000	9.118 %	1 M $
Shaun Bagai 2.736 %	292,540	2.736 %	392 004 $
Nixon Peabody Trust Co. LLC 0.9086 %	97,165	0.9086 %	130 201 $
Vanguard Group, Inc. (Subfiler) 0.5291 %	56,578	0.5291 %	75 815 $
Geode Capital Management LLC 0.5214 %	55,759	0.5214 %	74 717 $
Charles Schwab Investment Management, Inc. 0.4604 %	49,232	0.4604 %	65 971 $
Ramtin Agah 0.4438 %	47,460	0.4438 %	63 596 $
Kristen MacFarlane 0.3832 %	40,983	0.3832 %	54 917 $
Robert Spiegel 0.3832 %	40,983	0.3832 %	54 917 $

RenovoRx, Inc.

4546 El Camino Real Suite B1

94022, Los Altos

http://www.renovorx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.243 USD

Average target price

3.75 USD

Spread / Average Target

+201.69%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
RENOVORX, INC.	-45.72%	29.77M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs